A Study of Brentuximab Vedotin (SGN-35) in CD30-Positive Systemic Mastocytosis With or Without an Associated Hematological Clonal Non-Mast Cell Lineage Disease (AHNMD)
Phase of Trial: Phase II
Latest Information Update: 05 Feb 2019
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Systemic mastocytosis
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 16 Feb 2018 Status changed from recruiting to completed.
- 27 Jun 2017 Planned End Date changed from 1 Jun 2017 to 1 Dec 2017.